CJC-1295

[TODO] Hook — CJC-1295 as the next-generation GHRH analog, Drug Affinity Complex for extended half-life, two variants in research

What is CJC-1295?

• [TODO] Classification — modified GHRH(1-29) analog with amino acid substitutions for DPP-4 resistance
• [TODO] Two variants — CJC-1295 with DAC (Drug Affinity Complex) vs CJC-1295 no DAC (Mod GRF 1-29)
• [TODO] DAC — maleimidoproprionic acid linker, binds albumin, extends half-life to 6-8 days
• [TODO] No-DAC (Mod GRF 1-29) — half-life ~30 minutes, more pulsatile GH release
• [TODO] Developer — ConjuChem Biotechnologies

Mechanism of Action

• [TODO] Same GHRH receptor target as sermorelin — anterior pituitary somatotrophs
• [TODO] DAC variant — sustained GH elevation over days, “GH bleed” rather than pulse
• [TODO] No-DAC variant — preserves pulsatile GH pattern, often combined with GHRP
• [TODO] DPP-4 resistant — 4 amino acid substitutions prevent enzymatic degradation

Research Highlights

• [TODO] GH levels — DAC variant: 2-10x GH increase sustained for days
• [TODO] IGF-1 — significant elevation in clinical studies with both variants
• [TODO] Body composition — lean mass increases, fat mass reduction in animal models
• [TODO] Synergy — Mod GRF 1-29 + Ipamorelin = amplified GH pulse (popular research combo)

Dosing Protocols (Research Context)

• [TODO] CJC-1295 DAC — 1-2mg once or twice weekly (subcutaneous)
• [TODO] Mod GRF 1-29 (no DAC) — 100mcg 2-3x daily, before meals or before bed
• [TODO] Combination — Mod GRF + Ipamorelin at 100mcg each, pre-bed
• [TODO] Storage — standard peptide reconstitution, 2-8°C

Safety & Considerations

• [TODO] DAC variant — concern about non-physiological sustained GH elevation
• [TODO] Side effects — water retention, numbness/tingling (paresthesia), headache
• [TODO] No-DAC preferred — more researchers prefer pulsatile pattern for safety
• [TODO] Cortisol/prolactin — minimal effect (advantage over GHRP-6)

Häufig gestellte Fragen

Related Products

[TODO] Link to CJC-1295 product page + Growth Hormone category